Clinical trials: Liver Tumor
Colorectal Cancer, MSS
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
This is a multi-center, non-randomised Phase 1b study to evaluate the safety and tolerability of ATP128 alone or in combination with BI 754091 and of heterologous prime-boost ATP128 + VSV-GP128 in combination with BI 754091.
- Conditions
- Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- KISIMA-01 (NCT04046445)
- Testing
- ATP128, BI 754091, VSV-GP128
- Where
- 12 sites in United States, Belgium and 2 more
- Volunteers
- 96 people
- Sponsor
- Amal Therapeutics
Cancer
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
This Phase II study is conducted to assess the safety and efficacy of CPI-613 in patients with advanced and/or metastatic solid tumors for whom there there is no available therapy to provide clinical benefit or for those who have…
- Trial name
- NCT01832857
- Testing
- CPI-613
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Cornerstone Pharmaceuticals
Hepatocellular Cancer
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world…
- Trial name
- NCT02954094
- Where
- 71 sites in United States, France and 3 more
- Volunteers
- 10,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Adenocarcinoma, Neuroendocrine Tumors
EchoTip AcuCore Post-Market Clinical Study
The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the…
- Conditions
- Adenocarcinoma, Neuroendocrine Tumors, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT06358001
- Testing
- EchoTip AcuCore
- Where
- 8 sites in United States
- Volunteers
- 183 people
- Sponsor
- Cook Research Incorporated
Hepatocellular Carcinoma (HCC)
A Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres to Bridge or Downstage Patients With Hepatocellular Carcinoma (HCC) to Liver Transplant or Resection and Elicit Pathologic Necrosis.
This clinical investigation involves the use of an approved medical device (SIR-Spheres®) for a new purpose in patients with certain types of liver cancer.
- Trial name
- NCT07663487
- Testing
- SIR-Spheres Selectively Delivered to Liver Tumor
- Volunteers
- 78 people
- Sponsor
- Sirtex Medical
Motor Function, Cognitive Function
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Trial name
- ODYSSEY (NCT04373564)
- Testing
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain
- Where
- 51 sites in United States, Brazil and 6 more
- Volunteers
- 2,076 people
- Sponsor
- Guerbet
Hepatocellular Carcinoma
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein.
- Trial name
- REACH-2 (NCT02435433)
- Testing
- Ramucirumab
- Where
- 131 sites in United States, Australia and 18 more
- Volunteers
- 399 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted…
- Trial name
- NCT07479485
- Testing
- MRG006A, Pucotenlimab, Bevacizumab
- Where
- 8 sites in China
- Volunteers
- 160 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Hepatocellular Carcinoma (HCC)
A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of fisogatinib (formerly known as BLU…
- Trial name
- NCT02508467
- Testing
- Fisogatinib (BLU-554)
- Where
- 41 sites in United States, China and 10 more
- Volunteers
- 146 people
- Sponsor
- Blueprint Medicines Corporation
Cancer, Liver Cancer
A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.
- Conditions
- Cancer, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- PATRON (NCT01402908)
- Testing
- PI-88
- Where
- 25 sites in China, Hong Kong and 2 more
- Volunteers
- 520 people
- Sponsor
- Cellxpert Biotechnology Corp.
Carcinoma, Hepatocellular
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
Liver cancer is a good target for anti-angiogenic treatments such as pazopanib. The effect of pazopanib in patients with liver cancer are unknown.
- Trial name
- NCT00370513
- Testing
- pazopanib
- Where
- 3 sites in United States, Hong Kong and 1 more
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Liver Carcinoma, Hepatic Cell Carcinoma
A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infused autologous GPC3-directed CAR-T in patients with advanced hepatocellular carcinoma refractory to prior systematic…
- Trial name
- NCT06144385
- Testing
- CAR-GPC3 T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Hepatocellular Carcinoma
Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of Orantinib, an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, platelet-derived growth factor receptor, and fibroblast growth…
- Trial name
- NCT00784290
- Testing
- Orantinib (TSU-68)
- Where
- Japan
- Volunteers
- 35 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Advanced Solid Tumors, Lymphoma
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance.
- Conditions
- Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT03841110
- Testing
- FT500, Nivolumab, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Fate Therapeutics
Advanced Hepatocellular Carcinoma (HCC)
Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer
This trial is an open-label, dose-escalation, and randomized controlled Phase Ib/II clinical study for second-line treatment in participants with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT07282509
- Testing
- HA131, Enlonstobart Injection, Pembrolizumab Injection
- Volunteers
- 116 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Carcinoma, Hepatocellular
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
The purpose of this research study is to determine whether JX-594 (Pexa-Vec) has significant anti-tumoral activity and tolerability in primary hepatocellular carcinoma and to determine the dose to be used in further testing.
- Trial name
- NCT00554372
- Testing
- JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Jennerex Biotherapeutics
Carcinoma, Carcinoma, Hepatocellular
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in…
- Conditions
- Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasm
- Trial name
- MAApping (NCT05848947)
- Testing
- 99mTc-Macro Albumin Aggregate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sirtex Medical
Hepatocellular Carcinoma, Cholangiocarcinoma
A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced hepatobiliary cancer who have exhausted all currently approved standard anti-cancer treatment options.
- Trial name
- NCT02232633
- Testing
- BBI503
- Where
- 3 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Sumitomo Pharma America, Inc.
Solid Cancer
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed.
- Trial name
- NCT03890731
- Testing
- BAY73-4506 (Regorafenib, Stivarga)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 6 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
PI-88 in Hepatocellular Carcinoma After Hepatectomy
The purpose of this study is to evaluate the efficacy of PI-88 to inhibit or reduce tumor recurrence in patients with hepatocellular carcinoma following hepatectomy.
- Trial name
- NCT00247728
- Testing
- PI-88
- Where
- 6 sites in Taiwan
- Volunteers
- 172 people
- Sponsor
- Cellxpert Biotechnology Corp.